Company Marinus Pharmaceuticals, Inc.

MRNS

US56854Q2003

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Marinus Pharmaceuticals, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 18:17:56 30/04/2024 BST			5-day change	1st Jan Change
1.415 ^USD	+1.07%		-2.43%	-87.07%

04-17	Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	MT
04-16	Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	MT

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Companyâs new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Number of employees: 166

USD in Million	2022	Weight	2023	Weight	Delta
Therapeutics for Rare Seizures 100.0 %	25	100.0 %	31	100.0 %	+21.63%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	25	100.0 %	31	100.0 %	+21.63%

Managers	Title	Age	Since
Scott Braunstein CEO	Chief Executive Officer	60	04/09/18
Steven Pfanstiel DFI	Director of Finance/CFO	51	11/04/21
Joseph Hulihan CTO	Chief Tech/Sci/R&D Officer	68	05/11/19
Michael S. Saporito CTO	Chief Tech/Sci/R&D Officer	-	-
Sonya Weigle IRO	Public Communications Contact	-	31/08/21
Christy Shafer PRN	Corporate Officer/Principal	48	09/11/20
Kimberly McCormick LAW	General Counsel	-	-
Thomas Lyons PRN	Corporate Officer/Principal	-	31/12/17
Alex Aimetti PRN	Corporate Officer/Principal	-	-
Martha Manning LAW	General Counsel	69	14/06/20

Members of the board	Title	Age	Since
Tim Mayleben BRD	Director/Board Member	63	30/11/08
Scott Braunstein CEO	Chief Executive Officer	60	04/09/18
Elan Ezickson BRD	Director/Board Member	60	11/12/19
Seth Fischer BRD	Director/Board Member	68	05/09/16
Sara Nochur BRD	Director/Board Member	63	21/03/21
Sarah Noonberg BRD	Director/Board Member	56	15/05/23
Christine Silverstein BRD	Director/Board Member	41	25/01/23
Charles Austin BRD	Director/Board Member	68	28/07/20
Marvin Johnson BRD	Director/Board Member	61	17/04/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	54,938,349	54,400,357 ( 99.02 %)	7,307 ( 0.0133 %)	99.02 %

Name	Equities	%	Valuation
Suvretta Capital Management LLC 9.999 %	5,463,641	9.999 %	49 M $
Suvretta Capital Management LLC 9.784 %	5,346,119	9.784 %	48 M $
Eventide Asset Management LLC 8.290 %	4,529,997	8.290 %	41 M $
Tang Capital Management LLC 8.241 %	4,502,857	8.241 %	41 M $
BlackRock Advisors LLC 8.124 %	4,439,152	8.124 %	40 M $
Fiduciary Trust International LLC 7.016 %	3,833,955	7.016 %	35 M $
Cormorant Asset Management LP 5.948 %	3,250,000	5.948 %	29 M $
Avoro Capital Advisor LLC 5.765 %	3,150,000	5.765 %	28 M $
Jennison Associates LLC 5.415 %	2,959,161	5.415 %	27 M $
Vanguard Fiduciary Trust Co. 4.892 %	2,673,231	4.892 %	24 M $

Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center 100 Matsonford Road

19087-5279, Radnor

+484 801 4670

http://www.marinuspharma.com

address Marinus Pharmaceuticals, Inc.(MRNS)

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.4 USD

Average target price

8.778 USD

Spread / Average Target

+526.98%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
MARINUS PHARMACEUTICALS, INC.	-87.07%	76.89M
ELI LILLY AND COMPANY	+33.29%	664B
NOVO NORDISK A/S	+29.29%	567B
JOHNSON & JOHNSON	-7.29%	354B
MERCK & CO., INC.	+19.38%	330B
ABBVIE INC.	+4.85%	286B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.81%	148B

Other Pharmaceuticals